Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 09/12/22 | 8-K | Current report filing |
|
   |
37 |
| 08/29/22 | 8-K | Current report filing |
|
|
6 |
| 08/22/22 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
11 | |
| 08/11/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
105 |
| 08/11/22 | 8-K | Current report filing |
|
|
36 |
| 08/03/22 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
8 | |
| 06/03/22 | 4 | Statement of changes in beneficial ownership of securities |
|
3 | |
| 06/03/22 | 4 | Statement of changes in beneficial ownership of securities |
|
3 | |
| 06/03/22 | 4 | Statement of changes in beneficial ownership of securities |
|
3 | |
| 06/03/22 | 4 | Statement of changes in beneficial ownership of securities |
|
3 |
